SUNOSI
Total Payments
$10.1M
Transactions
47,810
Doctors
16,292
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1,610 | 1 | 1 |
| 2023 | $46,135 | 3 | 1 |
| 2022 | $2.9M | 8,324 | 4,738 |
| 2021 | $3.8M | 24,226 | 10,423 |
| 2020 | $1.1M | 7,054 | 3,725 |
| 2019 | $2.3M | 8,202 | 4,405 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.9M | 1,020 | 58.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.1M | 824 | 20.7% |
| Food and Beverage | $985,373 | 44,279 | 9.7% |
| Consulting Fee | $625,712 | 228 | 6.2% |
| Travel and Lodging | $309,239 | 1,247 | 3.1% |
| Grant | $212,484 | 7 | 2.1% |
| Education | $11,263 | 203 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $3,500 | 2 | 0.0% |
Payments by Type
Research
$5.9M
1,020 transactions
General
$4.2M
46,790 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CLINICAL TRIAL OF SOLRIAMFETOL FOR EXCESSIVE SLEEPINESS RELATED TO SHIFT WORK DISORDER | JAZZ PHARMACEUTICALS INC. | $1.8M | 0 |
| SOLRIAMFETOLS EFFECT ON COGNITIVE HEALTH IN APNEA PARTICIPANTS DURING A RANDOMIZED PLACEBO CONTROLLED STUDY: A 5 WEEK DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED, CROSSOVER, MULTICENTER STUDY OF SOLRIAMFETOL IN IMPROVING COGNITIVE FUNCTION IN PARTICIPANTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA PLUS IMPAIRED COGNITIVE FUNCTION | JAZZ PHARMACEUTICALS INC. | $598,825 | 1 |
| SOLRIAMFETOL IN A MURINE MODEL OF SLEEP APENA | JAZZ PHARMACEUTICALS INC. | $523,955 | 0 |
| SOLRIAMFETOL FOR ADHD IN ADULTS: A DOUBLE-BLIND PLACEBO CONTROLLED PILOT STUDY | JAZZ PHARMACEUTICALS INC. | $449,886 | 0 |
| SOLRIAMFETOL'S EFFECT ON COGNITIVE HEALTH IN APNEA PARTICIPANTS DURING A RANDOMIZED PLACEBO-CONTROLLED STUDY (SHARP): A 5-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED CROSSOVER MULTICENTER STUDY OF SOLRIAMFETOL IN IMPROVING COGNITIVE FUNCTION IN PARTICIPANTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA PLUS IMPAIRED COGNITIVE FUNCTION | JAZZ PHARMACEUTICALS INC. | $413,307 | 1 |
| SOLRIAMFETOL IN A MURINE MODEL OF SLEEP APNEA | JAZZ PHARMACEUTICALS INC. | $406,520 | 0 |
| A 4-WEEK STUDY OF THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF JZP-110 [(R)-2-AMINO-3-PHENYLPROPYLCARBAMATE HYDROCHLORIDE] IN SUBJECTS WITH PARKINSON'S DISEASE AND EXCESSIVE SLEEPINESS | JAZZ PHARMACEUTICALS INC. | $258,135 | 0 |
| ANALYSIS OF THE RISK OF MOTOR VEHICLE ACCIDENTS IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA | JAZZ PHARMACEUTICALS INC. | $200,842 | 0 |
| A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-CENTER, FLEXIBLE TITRATION STUDY EVALUATING THE EFFICACY OF SOLRIAMFETOL IN TREATING FATIGUE AND COGNITIVE SYMPTOMS IN ADULTS AGED 18-65 YEARS WITH A DIAGNOSIS OF MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME | JAZZ PHARMACEUTICALS INC. | $145,461 | 1 |
| A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SOLRIAMFETOL IN BINGE EATING DISORDER | JAZZ PHARMACEUTICALS INC. | $131,053 | 0 |
| THE LANGUAGE OF SLEEPINESS | JAZZ PHARMACEUTICALS INC. | $127,570 | 0 |
| A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED SINGLE-CENTER FLEXIBLE TITRATION STUDY EVALUATING THE EFFICACY OF SOLRIAMFETOL IN TREATING FATIGUE AND COGNITIVE SYMPTOMS IN ADULTS AGED 18-65 YEARS WITH A DIAGNOSIS OF MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME | JAZZ PHARMACEUTICALS INC. | $123,074 | 0 |
| ELUCIDATING THE CHANGES OF CEREBRAL BLOOD FLOW USING POSITIVE AIRWAY PRESSURE AND SORIAMFETOL AS MECHANISM OF DAYTIME SLEEPINESS IN OBSTRUCTIVE SLEEP APNEA USING MULTIMODAL MRI AND COGNITIVE TESTING | JAZZ PHARMACEUTICALS INC. | $120,408 | 0 |
| TWELVE-WEEK STUDY OF THE SAFETY AND EFFICACY OF JZP-110 IN THE TREATMENT OF EXCESSIVE SLEEPINESS IN OSA | JAZZ PHARMACEUTICALS INC. | $89,606 | 0 |
| SOLRIAMFETOL FOR POST STROKE WAKEFULNESS AND RECOVERY | JAZZ PHARMACEUTICALS INC. | $88,579 | 0 |
| LANGUAGE OF SLEEPINESS | JAZZ PHARMACEUTICALS INC. | $85,046 | 0 |
| TWELVE-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL-GROUP, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP-110 (R)-2-AMINO-3-PHENYLPROPYLCARBAMATE HYDROCHLORIDE IN THE TREATMENT OF EXCESSIVE SLEEPINESS IN SUBJECTS | Jazz Pharmaceuticals Inc. | $57,607 | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-AND POSITIVE-CONTROLLED, FOUR PERIOD CROSSOVER STUDY OF THE EFFECTS OF 300 MG AND 900 MG OF JZP -110 [(R)-2-AMINO-3-PHENYLPROPYLCARBAMATE HYDROCHLORIDE] ON QT/QTC INTERVALS IN HEALTHY SUBJECTS | JAZZ PHARMACEUTICALS INC. | $37,307 | 0 |
| BIOANALYSIS OF JZP-110 (SOLRIAMTETOL) IN HUMAN PLASMA BY LC-MS/MS IN SUPPORT OF PROTOCOL JZP188-301 | JAZZ PHARMACEUTICALS INC. | $36,000 | 0 |
| OPEN LABEL SAFETY STUDY OF SOLRIAMFETOL TO PROMOTE WAKEFULNESS AND IMPROVE COGNITION AND QUALITY OF LIFE IN PATIENTS WITH PRIMARY GLIOMAS | JAZZ PHARMACEUTICALS INC. | $32,050 | 0 |
Top Doctors Receiving Payments for SUNOSI — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , DO | Family Medicine | Beavercreek, OH | $38,895 | 80 |
| , M.D | Specialist | San Diego, CA | $37,611 | 52 |
| , M.D | Internal Medicine | Ventura, CA | $35,785 | 64 |
| , M.D | Pulmonary Disease | Saint Louis, MO | $35,313 | 35 |
| , MD | Sleep Medicine | Mobile, AL | $34,909 | 32 |
| , MD | Psychiatry | Maumee, OH | $33,968 | 66 |
| , MD | Neurology | Charlottesville, VA | $33,906 | 24 |
| , M.D | Psychiatry | Vancouver, WA | $33,057 | 50 |
| , M.D | Sleep Medicine | Cordova, TN | $27,961 | 62 |
| , MD | Internal Medicine | Miami, FL | $25,697 | 54 |
| , M.D | Psychiatry | Huntersville, NC | $25,592 | 33 |
| , MD | Family Medicine | Collegeville, PA | $25,108 | 25 |
| , MD | Pulmonary Disease | Novi, MI | $24,594 | 37 |
| , M.D | Neurology | Savannah, GA | $24,534 | 57 |
| , M.D | Neurology | Syracuse, NY | $23,660 | 18 |
| , N.P | Family | Houston, TX | $23,170 | 73 |
| Steven Manuli | — | Elizabeth City, NC | $20,660 | 32 |
| , MD | Critical Care Medicine | East Greenwich, RI | $20,232 | 13 |
| , MD | Sleep Medicine | Tomball, TX | $19,010 | 27 |
| , MD | Psychiatry | Madison, WI | $18,827 | 16 |
| , NP | Family | Charlottesville, VA | $18,573 | 57 |
| , D.O | Neurology | Worcester, MA | $16,462 | 28 |
| , M.D | Pulmonary Disease | Tucson, AZ | $16,200 | 4 |
| , M.D | Neurology | Kansas City, KS | $15,533 | 21 |
| , MD | Psychiatry | Minneapolis, MN | $14,343 | 36 |
Ad
Manufacturing Companies
- JAZZ PHARMACEUTICALS INC. $9.2M
- Jazz Pharmaceuticals Inc. $922,408
Product Information
- Type Drug
- Total Payments $10.1M
- Total Doctors 16,292
- Transactions 47,810
About SUNOSI
SUNOSI is a drug associated with $10.1M in payments to 16,292 healthcare providers, recorded across 47,810 transactions in the CMS Open Payments database. The primary manufacturer is JAZZ PHARMACEUTICALS INC..
Payment data is available from 2019 to 2024. In 2024, $1,610 was paid across 1 transactions to 1 doctors.
The most common payment nature for SUNOSI is "Unspecified" ($5.9M, 58.1% of total).
SUNOSI is associated with 20 research studies, including "CLINICAL TRIAL OF SOLRIAMFETOL FOR EXCESSIVE SLEEPINESS RELATED TO SHIFT WORK DISORDER" ($1.8M).